|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1151-1157.
Prepublished online as a Blood First Edition Paper on April 13, 2006; DOI 10.1182/blood-2005-12-4956.
Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
Stephen Breit,
Martin Stanulla,
Thomas Flohr,
Martin Schrappe,
Wolf-Dieter Ludwig,
Gabriele Tolle,
Margit Happich,
Martina U. Muckenthaler, and
Andreas E. Kulozik
From the Department of Pediatric Oncology, Hematology, and Immunology, University of Heidelberg; the Department of Pediatric Hematology and Oncology, Hannover Medical School; the Institute of Human Genetics, University of Heidelberg; the Department of General Pediatrics, University Medical Centre Schleswig-Holstein, Campus Kiel; and the Department of Hematology, Oncology, and Tumor Immunology, Robert-Rössle-Clinic at the HELIOS Clinic Berlin-Buch, Charité Medical School, Berlin, Germany.
Activating mutations of the transmembrane receptor NOTCH1 are common in precursor T-cell lymphoblastic leukemia (T-ALL). We systematically analyzed the impact of activating NOTCH1 mutations on early treatment response and long-term outcome in 157 patients with T-ALL of the pediatric ALLBerlin-Frankfurt-Munster (BFM) 2000 study. We confirm previous results that NOTCH1 mutations occur in more than 50% of T-ALL in children. In 82 patients (82/157; 52.2%), activating NOTCH1 mutations were identified either in the heterodimerization (55/82; 67.1%), in the PEST (13/82; 15.9%), or in both domains (14/82; 17.0%). The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood cell count, and T-cell immunophenotype at the time of diagnosis. Furthermore, activating NOTCH1 mutations specified a large subgroup of patients with an excellent prognosis. These findings indicate that in the context of the ALL-BFM 2000 treatment strategy, NOTCH1 mutations predict a more rapid early treatment response and a favorable long-term outcome in children with T-ALL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
NOTCH1: prognostic factor or molecular target?
- Stephen P. Hunger
Blood 2006 108: 1117-1118.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
C. D. Baldus, J. Thibaut, N. Goekbuget, A. Stroux, C. Schlee, M. Mossner, T. Burmeister, S. Schwartz, C. D. Bloomfield, D. Hoelzer, et al.
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia
Haematologica,
October 1, 2009;
94(10):
1383 - 1390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Mansour, M. L. Sulis, V. Duke, L. Foroni, S. Jenkinson, K. Koo, C. G. Allen, R. E. Gale, G. Buck, S. Richards, et al.
Prognostic Implications of NOTCH1 and FBXW7 Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol
J. Clin. Oncol.,
September 10, 2009;
27(26):
4352 - 4356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Remke, S. Pfister, C. Kox, G. Toedt, N. Becker, A. Benner, W. Werft, S. Breit, S. Liu, F. Engel, et al.
High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-{beta} and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response
Blood,
July 30, 2009;
114(5):
1053 - 1062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. R. Gordon, M. Roy, D. Vardar-Ulu, M. Garfinkel, M. R. Mansour, J. C. Aster, and S. C. Blacklow
Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL
Blood,
April 30, 2009;
113(18):
4381 - 4390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Asnafi, A. Buzyn, S. Le Noir, F. Baleydier, A. Simon, K. Beldjord, O. Reman, F. Witz, T. Fagot, E. Tavernier, et al.
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study
Blood,
April 23, 2009;
113(17):
3918 - 3924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Armstrong, P. B. de la Grange, B. Gerby, M.-C. Rouyez, J. Calvo, M. Fontenay, N. Boissel, H. Dombret, A. Baruchel, J. Landman-Parker, et al.
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity
Blood,
February 19, 2009;
113(8):
1730 - 1740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Graziani, S. Eliasz, M. A. De Marco, Y. Chen, H. I. Pass, R. M. De May, P. R. Strack, L. Miele, and M. Bocchetta
Opposite Effects of Notch-1 and Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through the Akt Pathway
Cancer Res.,
December 1, 2008;
68(23):
9678 - 9685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al.
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome
Haematologica,
November 1, 2008;
93(11):
1658 - 1665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Sulis, O. Williams, T. Palomero, V. Tosello, S. Pallikuppam, P. J. Real, K. Barnes, L. Zuurbier, J. P. Meijerink, and A. A. Ferrando
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL
Blood,
August 1, 2008;
112(3):
733 - 740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. V. Balgobind, P. Van Vlierberghe, A. M. W. van den Ouweland, H. B. Beverloo, J. N. R. Terlouw-Kromosoeto, E. R. van Wering, D. Reinhardt, M. Horstmann, G. J. L. Kaspers, R. Pieters, et al.
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis
Blood,
April 15, 2008;
111(8):
4322 - 4328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. De Keersmaecker, I. Lahortiga, N. Mentens, C. Folens, L. Van Neste, S. Bekaert, P. Vandenberghe, M. D. Odero, P. Marynen, and J. Cools
In vitro validation of {gamma}-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
Haematologica,
April 1, 2008;
93(4):
533 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Strehl, K. Nebral, M. Konig, J. Harbott, H. Strobl, R. Ratei, S. Struski, B. Bielorai, M. Lessard, M. Zimmermann, et al.
ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations
Clin. Cancer Res.,
February 15, 2008;
14(4):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Campana
Molecular Determinants of Treatment Response in Acute Lymphoblastic Leukemia
Hematology,
January 1, 2008;
2008(1):
366 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Mansour, V. Duke, L. Foroni, B. Patel, C. G. Allen, P. J. Ancliff, R. E. Gale, and D. C. Linch
Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
December 1, 2007;
13(23):
6964 - 6969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cario, S. Izraeli, A. Teichert, P. Rhein, J. Skokowa, A. Moricke, M. Zimmermann, A. Schrauder, L. Karawajew, W.-D. Ludwig, et al.
High Interleukin-15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia With Involvement of the CNS
J. Clin. Oncol.,
October 20, 2007;
25(30):
4813 - 4820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bergeron, E. Clappier, I. Radford, A. Buzyn, C. Millien, G. Soler, P. Ballerini, X. Thomas, J. Soulier, H. Dombret, et al.
Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs
Blood,
October 1, 2007;
110(7):
2324 - 2330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Winter, Z. Jiang, H. M. Khawaja, T. Griffin, M. Devidas, B. L. Asselin, and R. S. Larson
Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood,
September 1, 2007;
110(5):
1429 - 1438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Malyukova, T. Dohda, N. von der Lehr, S. Akhondi, M. Corcoran, M. Heyman, C. Spruck, D. Grander, U. Lendahl, and O. Sangfelt
The Tumor Suppressor Gene hCDC4 Is Frequently Mutated in Human T-Cell Acute Lymphoblastic Leukemia with Functional Consequences for Notch Signaling
Cancer Res.,
June 15, 2007;
67(12):
5611 - 5616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Huang, S. Duan, W. K. Bleibel, E. O. Kistner, W. Zhang, T. A. Clark, T. X. Chen, A. C. Schweitzer, J. E. Blume, N. J. Cox, et al.
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity
PNAS,
June 5, 2007;
104(23):
9758 - 9763.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|